Gastric Cancer Therapy Market

Market Overview The Global Gastric Cancer Therapy Market is projected to expand significantly, increasing from USD 4.15 Billion in 2025 to USD 6.11 Billion by 2031, demonstrating a Compound Annual Growth Rate (CAGR) of 6.66%. This market includes a variety of pharmacological and biological treatments for stomach lining malignancies, such as chemotherapy, targeted therapies, and immunomodulators. Its growth is primarily fueled by the increasing global incidence of gastric carcinoma, driven by an aging population and changing dietary habits, which creates a pressing need for effective treatments. Furthermore, the market benefits from a rise in regulatory approvals for innovative drug formulations, accelerating the introduction of advanced therapeutic options.However, the market encounters a considerable hurdle due to the substantial costs associated with the development and administration of complex biologic drugs, which restricts patient access, particularly in regions sensitive to healthcare expenses. This financial barrier is frequently worsened by strict reimbursement policies that delay the adoption of high-value therapies. The persistent impact of this disease is underscored by statistics from the American Cancer Society, which reported an estimated 30,300 new cases of stomach cancer and 10,780 related deaths in the United States in 2025. Market Driver The Global Gastric Cancer Therapy Market is undergoing a significant transformation, primarily driven by the increasing adoption of novel immunotherapy regimens, which are progressively replacing conventional chemotherapy as the standard of care for advanced-stage gastric cancer. Immune checkpoint inhibitors, especially PD-1/PD-L1 antagonists, have demonstrated superior clinical outcomes, leading to their broad integration into first-line treatment protocols. This therapeutic shift is substantially boosting market value, evidenced by the commercial success of prominent biologic agents. For example, Merck reported in February 2025 that Keytruda generated $29.5 billion in total sales for 2024, a growth trajectory partly attributable to its expanded indications in gastrointestinal malignancies. The clinical efficacy driving this adoption is further highlighted by regulatory milestones, with the FDA's March 2025 approval of pembrolizumab for HER2-positive gastric or gastroesophageal junction adenocarcinoma, noting a confirmed overall response rate of 73% for the combination therapy, validating its potency in improving patient outcomes.Concurrently, the advancement of targeted therapeutic agents, including antibody-drug conjugates (ADCs) and therapies focusing on biomarkers like HER2 and Claudin 18.2, represents a crucial growth engine. These agents provide precise treatment options that minimize systemic toxicity while maximizing tumor eradication, addressing the urgent demand for personalized medicine. The market impact of these sophisticated therapies is both immediate and substantial, as they capture significant revenue share shortly after approval. Illustrating this rapid market penetration, BioPharma Dive reported in May 2025 that the targeted antibody-drug conjugate Enhertu amassed over $3 billion in 2024 revenue, underscoring the lucrative potential of precision oncology assets within the gastric cancer segment. Market Challenge The substantial costs associated with the development and administration of complex biologic drugs pose a significant barrier to the expansion of the Global Gastric Cancer Therapy Market. These advanced therapeutics frequently carry premium price tags that surpass the financial capabilities of healthcare systems in developing nations and strain budgets in developed economies. As a result, patient access is severely limited in cost-sensitive regions, where the disease burden is often highest, directly curtailing the volume of therapies administered and dampening overall market revenue growth.This financial pressure leads payers to enforce stringent reimbursement policies and delay coverage approvals for novel treatments, thereby impeding the commercial uptake of these drugs. The escalating expense of oncology management is evident in recent industry data; according to the International Foundation of Employee Benefit Plans, the median spend on cancer care by employers increased by 11 percent in 2025 compared to the previous year. Such rising costs compel healthcare providers and insurers to prioritize less expensive alternatives over innovative biologic interventions, consequently stalling the widespread adoption of new gastric cancer therapies and reducing the potential return on investment for pharmaceutical developers. Market Trends The proliferation of bispecific antibody clinical programs is significantly transforming the market by enabling the simultaneous targeting of distinct tumor-associated antigens or immune checkpoints. This dual-targeting mechanism addresses the limitations of monospecific antibodies, such as tumor heterogeneity and drug resistance, by enhancing binding specificity and triggering more potent immune responses. Developers are actively advancing assets that target combinations like HER2/HER2, PD-1/CTLA-4, and Claudin 18.2/4-1BB to improve treatment durability in advanced gastric cancer. Validating this therapeutic potential, Jazz Pharmaceuticals announced in January 2026 that the bispecific antibody Ziihera demonstrated a median overall survival benefit exceeding two years in first-line HER2+ locally advanced or metastatic GEA, establishing a new benchmark for efficacy in this patient population.Concurrently, the integration of liquid biopsy for non-invasive monitoring is expanding as a crucial method for early detection and longitudinal disease assessment. This technology addresses the challenges associated with traditional tissue biopsies by analyzing circulating tumor DNA to guide treatment selection and detect recurrence earlier. The shift towards incorporating these diagnostics into large-scale clinical protocols highlights their increasing utility in standardizing patient management. Illustrating this commitment to validation, Guardant Health announced in July 2025 the enrollment of the first patient in the National Cancer Institute's Vanguard Study, which aims to rigorously evaluate the performance of its Shield Multi-Cancer Detection Test in identifying various malignancies, including gastric cancer, by enrolling up to 24,000 participants. Key Market Players * Abbott Laboratories Inc. * Amgen, Inc. * Celltrion Inc. * Novartis AG * F. Hoffmann-La Roche Ltd * Agilent Technologies Inc. * AstraZeneca Plc * Pfizer Inc. * Eli Lilly & Co. * GlaxoSmithKline Plc Report Scope In this report, the Global Gastric Cancer Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below: # Gastric Cancer Therapy Market, By Therapy Type * Chemotherapy * Targeted Therapy * Immunotherapy * Radiation Therapy * Surgery # Gastric Cancer Therapy Market, By End User * Ambulatory Surgery Centers * Hospitals and Specialty Clinics * Other # Gastric Cancer Therapy Market, By Region * North America United States Canada Mexico * Europe France United Kingdom Italy Germany Spain * Asia Pacific China India Japan Australia South Korea * South America Brazil Argentina Colombia * Middle East & Africa South Africa Saudi Arabia UAE Competitive Landscape Company Profiles: Detailed analysis of the major companies present in the Global Gastric Cancer Therapy Market. Available Customizations: Global Gastric Cancer Therapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: Company Information * Detailed analysis and profiling of additional market players (up to five).